Heart failure & cardiomyopathies
Safety and Efficacy of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy: A 36-Week Analysis from FOREST-HCM
Authors' conclusion
Over 36 weeks, aficamten appeared safe and effective in the studied patients with nHCM.
Study context
- Population
- Patients with non-obstructive hypertrophic cardiomyopathy (nHCM); mean age 57.2 ± 15.3 years, 62% female, 41% NYHA class III
- Participants
- 34 patients
- Outcome
- Safety and efficacy
- Follow-up
- 36 weeks
Methodological details36-week analysis of the ongoing FOREST-HCM trial, left ventricular ejection fraction (LVEF)-guided dose titration
- 36-week analysis of the ongoing FOREST-HCM trial
- LVEF-guided dose titration
Main finding
As reported in the abstract
- Achieved 15-20 mg daily dose
- 82.3%
- Change in LVEF from 70% ± 6.1 (p < 0.0001)
- −4.3% ± 5.2
- NYHA class improved by ≥1 class at Week 36, n (%)
- 27 (79.4%)
- Mean change in KCCQ clinical summary score vs baseline (points)
- 13.8 ± 12.5
- Median (IQR) change in NT-proBNP from baseline (p < 0.0001)
- −665.5 pg/ml [−1244.0, −232.0]
- Median (IQR) change in hs-cTnI, unchanged (p = 0.25)
- −2.7 ng/L [−11.3, 1.6]
Safety
Drug discontinuations due to AEs · 36 weeks
- No drug discontinuations due to adverse events
LVEF <50% · 36 weeks
- LVEF <50% occurred in 2 patients (one following pulmonary vein isolation, one associated with AF)
- 5.9%
Change in LVEF · 36 weeks
- Modest reduction in LVEF from 70% ± 6.1 (mean ± SD)
- −4.3% ± 5.2 (p < 0.0001)
Original publication
Safety and Efficacy of Aficamten in Patients with Non-Obstructive Hypertrophic Cardiomyopathy: A 36-Week Analysis from FOREST-HCM. Eur J Heart Fail. Published 18 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →